Clinical trial
Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone…
NCT00248703 · Oslo University Hospital, Other · Completed
Key facts
| NCT number | NCT00248703 |
|---|---|
| Title | Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow |
| Official title | Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment |
| Lead sponsor | Oslo University Hospital, Other |
| Collaborators | University of Tromso Helse Stavanger HF Sorlandet Hospital HF Sykehuset Innlandet HF Ullevaal University Hospital Sykehuset i Vestfold HF Sykehuset Ostfold Alesund Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel |
| Enrollment | 1,128 |
| Start date | Oct 1, 2003 |
| Primary completion | Nov 1, 2012 |
| Completion | Apr 1, 2022 |
| First posted | Nov 4, 2005 |
| Last update posted | Apr 22, 2022 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: